3-phenyl-1-(3-hydroxyphenyl)propanol | 152754-60-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: 3-phenyl-1-(3-hydroxyphenyl)propanol
• 英文别名: 3-(1-Hydroxy-3-phenylpropyl)phenol
• CAS: 152754-60-4
• 化学式: C₁₅H₁₆O₂
• 分子量: 228.291
• InChiKey: WUQVHVIQCYILOL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-phenyl-1-(3-hydroxyphenyl)propanol 在 chromium(VI) oxide 、 硫酸 作用下， 以 丙酮 为溶剂， 以84%的产率得到1-(3-hydroxyphenyl)-3-phenyl-1-propanone
  参考文献：
  名称：

  Design, synthesis, and kinetic evaluation of high-affinity FKBP ligands and the X-ray crystal structures of their complexes with FKBP12

  摘要：

  The design and synthesis of high-affinity FKBP12 ligands is described. These compounds potently inhibit the cis-trans-peptidylprolyl isomerase (rotamase) activity catalyzed by FKBP12 with inhibition constants (K(i,app)) as low as 1 nM, yet they possess remarkable structural simplicity relative to FK506 and rapamycin, from which they are conceptually derived. The atomic structures of three FKBP12-ligand complexes and of one unbound ligand were determined by X-ray crystallography and are compared to the FKBP12-FK506 and FKBP12-rapamycin complexes.

  DOI：

  10.1021/ja00075a008
• 作为产物：
  描述：

  magnesium,ethylbenzene,bromide 、 间羟基苯甲醛 以 四氢呋喃 为溶剂， 反应 4.0h， 以58.3%的产率得到3-phenyl-1-(3-hydroxyphenyl)propanol
  参考文献：
  名称：

  Design, synthesis, and kinetic evaluation of high-affinity FKBP ligands and the X-ray crystal structures of their complexes with FKBP12

  摘要：

  The design and synthesis of high-affinity FKBP12 ligands is described. These compounds potently inhibit the cis-trans-peptidylprolyl isomerase (rotamase) activity catalyzed by FKBP12 with inhibition constants (K(i,app)) as low as 1 nM, yet they possess remarkable structural simplicity relative to FK506 and rapamycin, from which they are conceptually derived. The atomic structures of three FKBP12-ligand complexes and of one unbound ligand were determined by X-ray crystallography and are compared to the FKBP12-FK506 and FKBP12-rapamycin complexes.

  DOI：

  10.1021/ja00075a008

文献信息

• Diaminocyclopentadienone Ruthenium Complex Catalyzed Alkylation of Indoles and Ketones with Primary Alcohols
  作者：Steffen Skowaisa、Edgar Haak

  DOI：10.1002/ejoc.202300707

  日期：——

  The borrowing hydrogen approach allows the direct utilization of non-activated alcohols as alkylating agents. A readily available, air and moisture stable ruthenium complex proves to be a particularly effective hydrogen autotransfer catalyst for the alkylation of various indoles or ketones with poorly reactive alcohols.

  借氢方法允许直接利用非活化醇作为烷基化剂。一种容易获得的、空气和湿气稳定的钌络合物被证明是一种特别有效的氢自转移催化剂，用于各种吲哚或酮与反应性差的醇的烷基化。
• US6316405B1
  申请人：——

  公开号：US6316405B1

  公开（公告）日：2001-11-13
• US8106191B2
  申请人：——

  公开号：US8106191B2

  公开（公告）日：2012-01-31
• [EN] CYCLOSPORIN A CONJUGATES AND USES THEREFOR<br/>[FR] CONJUGUES DE CYCLOSPORINE A ET UTILISATIONS
  申请人：WISCONSIN ALUMNI RESEARCH FOUNDATION

  公开号：WO1999010374A1

  公开（公告）日：1999-03-04

  (EN) Disclosed are conjugates of A$g(b)-binding peptides and CsA analogs and conjugates of A$g(b)-binding peptides and FK506 Binding Peptide inhibitors. These conjugates chemically induce dimerization of either cyclophilin or FK506 Binding Peptide with A$g(b) peptide, a major component of amyloid plaques found in neurological disorders such as Alzheimer's disease, multiple sclerosis, and amyotrophic lateral sclerosis. The conjugates are useful in the treatment of neurological diseases involving the formation of amyloid plaques because they inhibit and/or prevent the aggregation and deposition of A$g(b) peptide into plaques.(FR) Cette invention a trait à des conjugués fragment de peptide A$g(b) de fixation - analogues de cyclosporine A (CsA) et à des conjugués fragment de peptide A$g(b) de fixation inhibiteurs de peptides fixés au macrolide FK506. Ces conjugués induisent par la voie chimique une dimérisation soit de la cyclophiline, soit du peptide fixé au macrolide FK506, avec le peptide A$g(b), un composant essentiel de plaques amyloïdes présentes en cas de troubles neurologiques tels que la maladie d'Alzheimer, la sclérose en plaques et la sclérose latérale amyotrophique. Ces conjugués sont utilisés pour traiter des troubles neurologiques impliquant la formation de plaques amyloïdes car ils inhibent et/ou empêchent l'agrégation et le dépôt de peptides A$g(b) sous forme de plaques.
• Design, synthesis, and kinetic evaluation of high-affinity FKBP ligands and the X-ray crystal structures of their complexes with FKBP12
  作者：Dennis A. Holt、Juan I. Luengo、Dennis S. Yamashita、Hye Ja Oh、Arda L. Konialian、Hwa Kwo Yen、Leonard W. Rozamus、Martin Brandt、Mary J. Bossard、Mark A. Levy、Drake S. Eggleston、Jun Liang、L. Wayne Schultz、Thomas J. Stout、Jon Clardy

  DOI：10.1021/ja00075a008

  日期：1993.11.1

  The design and synthesis of high-affinity FKBP12 ligands is described. These compounds potently inhibit the cis-trans-peptidylprolyl isomerase (rotamase) activity catalyzed by FKBP12 with inhibition constants (K(i,app)) as low as 1 nM, yet they possess remarkable structural simplicity relative to FK506 and rapamycin, from which they are conceptually derived. The atomic structures of three FKBP12-ligand complexes and of one unbound ligand were determined by X-ray crystallography and are compared to the FKBP12-FK506 and FKBP12-rapamycin complexes.